Evidence map›Paper›PMID 24503129›Full record

ArticleGastroenterology2014

Vascular endothelial growth factor promotes fibrosis resolution and repair in mice.

Liu Yang, Junghee Kwon, Yury Popov, Gabriella B Gajdos, Tamas Ordog, Rolf A Brekken, Debabrata Mukhopadhyay, Detlef Schuppan, Yan Bi, Douglas Simonetto and 1 more

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 251 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Liu YangDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Junghee KwonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Yury PopovDivision of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Gabriella B GajdosDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Tamas OrdogDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Rolf A BrekkenHamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, UT Southwestern Medical Center, Dallas, Texas.
Debabrata MukhopadhyayDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota.
Detlef SchuppanDivision of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Yan BiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Douglas SimonettoDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Vijay H ShahDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: shah.vijay@mayo.edu.
Mayo Clinic · USWinnMed · USBeth Israel Deaconess Medical Center · USHarvard University · USThe University of Texas Southwestern Medical Center · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
Molecular Mechanisms of Portal HypertensionR01DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2002 to 2023
$6.4M
Molecular Mechanisms of Liver Fibrosis (Diversity Supplement)R37AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH · 2019 to 2026
$3.0M
Viral, T Cell, &Cytokine Determinants of Stellate CellU19AI066313 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KOZIEL, MARGARET J · 2005 to 2009
$2.6M
Molecular Mechanisms of Liver FibrosisR01AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2012 to 2018
$2.5M
Identification of Serum Markers of Liver Fibrogenesis/ Fibrolysis by ProteomicsR21DK076873 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SCHUPPAN, DETLEF · 2007 to 2008
$462k
NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA142543NIAAA NIH HHS AA021171NIAAA NIH HHS R01 AA021171NIAAA NIH HHS R37 AA021171NIAID NIH HHS U19 AI066313NIDDK NIH HHS 1R21A1 DK076873NIDDK NIH HHS DK59015NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK059615NIDDK NIH HHS R21 DK076873
6 · The paper itself

Abstract

BACKGROUND &

aimsVascular endothelial growth factor (VEGF)-induced angiogenesis is implicated in fibrogenesis and portal hypertension. However, the function of VEGF in fibrosis resolution has not been explored.

methodsWe developed a cholecystojejunostomy procedure to reconstruct biliary flow after bile duct ligation in C57BL/6 mice to generate a model of fibrosis resolution. These mice were then given injections of VEGF-neutralizing (mcr84) or control antibodies, and other mice received an adenovirus that expressed mouse VEGF or a control vector. The procedure was also performed on macrophage fas-induced apoptosis mice, in which macrophages can be selectively depleted. Liver and blood samples were collected and analyzed in immunohistochemical, morphometric, vascular permeability, real-time polymerase chain reaction, and flow cytometry assays.

resultsVEGF-neutralizing antibodies prevented development of fibrosis but also disrupted hepatic tissue repair and fibrosis resolution. During fibrosis resolution, VEGF inhibition impaired liver sinusoidal permeability, which was associated with reduced monocyte migration, adhesion, and infiltration of fibrotic liver. Scar-associated macrophages contributed to this process by producing the chemokine (C-X-C motif) ligand 9 (CXCL9) and matrix metalloproteinase 13. Resolution of fibrosis was impaired in macrophage fas-induced apoptosis mice but increased after overexpression of CXCL9.

conclusionsIn a mouse model of liver fibrosis resolution, VEGF promoted fibrogenesis, but was also required for hepatic tissue repair and fibrosis resolution. We observed that VEGF regulates vascular permeability, monocyte infiltration, and scar-associated macrophages function.

Indexed as

Liver RegenerationAdenoviridaeAnimalsAntibodies, NeutralizingApoptosisBile DuctsCapillary PermeabilityCarbon TetrachlorideCells, CulturedChemokine CXCL9CholecystostomyCoculture Techniquesfas ReceptorGenetic VectorsGene Transfer TechniquesHumansAntibodies, NeutralizingCarbon TetrachlorideChemokine CXCL9Cxcl9 protein, mouseFas protein, mousefas ReceptorMatrix Metalloproteinase 13Mmp13 protein, mouseReceptor, Macrophage Colony-Stimulating FactorTacrolimus Binding Protein 1AVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseExtracellular MatrixHepatic SinusoidLiver DamageSinusoidal Endothelial Cell

Identifiers

PMID24503129
PMCPMC4001704
OpenAlexW1990139802

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.